At PM Life Sciences Consulting, we help investors and boards make confident decisions in complex science-driven markets. Our due diligence and investor support services combine deep medical, regulatory, and commercial expertise to uncover hidden risks and surface real value.

We know that great science isn’t enough. You need to understand how a product fits the clinical landscape, what payers will really fund, and whether the team can deliver. That’s where we come in.

We offer:

• Technical due diligence on pipeline assets - from preclinical to post-launch

• Access and reimbursement risk assessments, including NICE/SMC feasibility

• Clinical development & trial design evaluation for scalability and relevance

• Medical team and leadership capability reviews

• Scientific communications and positioning audits for investor and partner materials

Whether you're investing in a Series A or considering an acquisition, we bring a sharp, experienced eye to medical aspects - spotting red flags, pressure testing assumptions, and identifying what it takes to succeed post-funding.

We also support early-stage companies in preparing for investment - sharpening their evidence strategy, access story, and medical infrastructure plans to stand up to tough questions and investor scrutiny.

From VCs and family offices to corporate development teams, we can to go deeper than the data room - and give advice that’s grounded, strategic, and investor-savvy.